Last reviewed · How we verify
PIPAC
At a glance
| Generic name | PIPAC |
|---|---|
| Also known as | Cisplatin, Doxorubicin, Oxaliplatin |
| Sponsor | Michael Bau Mortensen |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of PIPAC Using Single Agent Mitomycin in Solid Tumors (PHASE1)
- Evaluation of Pressurized Intraperitoneal Aerosol Chemotherapy With VRT106 Versus PIPAC in Patients With Advanced Gastric Cancer and PeritonealMetastasis: A Prospective, Multicenter, Open-Label, Randomized Controlled Trial (PHASE2)
- The PIPAC-OPC7 Study: The Use of PET/CT Scans as a Method of Evaluation in Patients Treated With PIPAC, a Pilot Study.
- Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases (PHASE1)
- Heated Versus Aerosol-based Laparoscopic Chemotherapy for Cancer That Has Spread to the Peritoneum (Abdominal Lining) (PHASE2)
- Treatment of Malignant Peritoneal Mesothelioma (MESOTIP) (PHASE2)
- A Prospective, Safety, and Efficacy Clinical Trial of Pressurized Intraperitoneal Aerosol Therapy for Peritoneal Metastasis of Colorectal Cancer (PHASE1)
- Chewing Gum Flavors to Reduce Postoperative Nausea and Vomiting After PIPAC (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PIPAC CI brief — competitive landscape report
- PIPAC updates RSS · CI watch RSS
- Michael Bau Mortensen portfolio CI